3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Neoplasms by Histologic Type
1
Neoplasms
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid
1
Leukemia
1
Hematologic Diseases
1
Bone Marrow Diseases
1
Interventions
Cyclophosphamide
125
fludarabine phosphate
116
Busulfan
98
Peripheral Blood Stem Cell Transplantation
88
Filgrastim
73
Antilymphocyte Serum
72
Tacrolimus
67
Cytarabine
67
Cyclosporine
64
Mycophenolic Acid
63
Methotrexate
57
Radiotherapy
54
fludarabine
52
Whole-Body Irradiation
52
Melphalan
49
Imatinib Mesylate
41
Azacitidine
35
Methylprednisolone
34
Etoposide
33
Cord Blood Stem Cell Transplantation
30
Granulocyte Colony-Stimulating Factor
28
sargramostim
26
Thiotepa
26
Decitabine
21
Alemtuzumab
21
Clofarabine
20
thymoglobulin
19
Stem Cell Transplantation
19
nilotinib
18
Interferon-alpha
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
BID protein, human
×
Myeloid
×
Clear all
NCT02627677
2021-11-26
OPTIC-2L
Takeda
Phase 3
Terminated
44 enrolled
22 charts